Literature DB >> 7663785

Evolution of rifampin resistance in human immunodeficiency virus-associated tuberculosis.

C M Nolan1, D L Williams, M D Cave, K D Eisenach, H el-Hajj, T M Hooton, R L Thompson, S V Goldberg.   

Abstract

Acquired rifampin resistance without preexisting isoniazid resistance is highly unusual in patients with tuberculosis. The purpose of this report is to describe and characterize that unusual pattern of acquired drug resistance in three patients with human immunodeficiency virus (HIV) infection. The patients originally had Mycobacterium tuberculosis strains that were susceptible to isoniazid and rifampin. During treatment in two patients and after completion of therapy in the remaining one, each patient developed active, rifampin-resistant, isoniazid-susceptible tuberculosis. One patient subsequently developed isoniazid resistance also. Studies on patients' M. tuberculosis isolates using IS6110 restriction fragment length polymorphism typing and rpoB gene sequencing indicated that rifampin resistance in each patient arose during therapy by an rpoB gene mutation in the original M. tuberculosis isolate. Detection of this unusual drug-resistance phenotype in three patients with HIV infection suggests that acquired rifampin resistance is somehow associated with co-infection due to HIV and tuberculosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7663785     DOI: 10.1164/ajrccm.152.3.7663785

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  13 in total

1.  Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations.

Authors:  S L Moghazeh; X Pan; T Arain; C K Stover; J M Musser; B N Kreiswirth
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

2.  Immunodeficiency and Intermittent Dosing Promote Acquired Rifamycin Monoresistance in Murine Tuberculosis.

Authors:  Sang-Won Park; Rokeya Tasneen; Paul J Converse; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

3.  Bacteriological and molecular analysis of rifampin-resistant Mycobacterium tuberculosis strains isolated in Australia.

Authors:  L K Yuen; D Leslie; P J Coloe
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

4.  Cross-matching TB and AIDS registries: TB patients with HIV co-infection, United States, 1993-1994.

Authors:  M Moore; E McCray; I M Onorato
Journal:  Public Health Rep       Date:  1999 May-Jun       Impact factor: 2.792

5.  Evaluation of the INNO-LiPA Rif. TB assay, a reverse hybridization assay for the simultaneous detection of Mycobacterium tuberculosis complex and its resistance to rifampin.

Authors:  R Rossau; H Traore; H De Beenhouwer; W Mijs; G Jannes; P De Rijk; F Portaels
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

Review 6.  Timing of antiretroviral therapy for HIV in the setting of TB treatment.

Authors:  Damani A Piggott; Petros C Karakousis
Journal:  Clin Dev Immunol       Date:  2010-12-27

Review 7.  New approaches in the diagnosis and treatment of latent tuberculosis infection.

Authors:  Suhail Ahmad
Journal:  Respir Res       Date:  2010-12-03

8.  Potential for adaptation overrides cost of resistance.

Authors:  Jorge Moura de Sousa; Ana Sousa; Catarina Bourgard; Isabel Gordo
Journal:  Future Microbiol       Date:  2015-09-07       Impact factor: 3.165

9.  Multidrug-resistant Mycobacterium tuberculosis in HIV-infected persons, Peru.

Authors:  Pablo E Campos; Pedro G Suarez; Jorge Sanchez; David Zavala; Jorge Arevalo; Eduardo Ticona; Charles M Nolan; Thomas M Hooton; King K Holmes
Journal:  Emerg Infect Dis       Date:  2003-12       Impact factor: 6.883

10.  Low Occurrence of Tuberculosis Drug Resistance among Pulmonary Tuberculosis Patients from an Urban Setting, with a Long-Running DOTS Program in Zambia.

Authors:  Chanda Mulenga; Allan Chonde; Innocent C Bwalya; Nathan Kapata; Mathilda Kakungu-Simpungwe; Sven Docx; Krista Fissette; Isdore Chola Shamputa; Françoise Portaels; Leen Rigouts
Journal:  Tuberc Res Treat       Date:  2010-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.